Here are Tuesday’s biggest calls on Wall Street:
Key said it’s standing by the stock after a series of supply chain checks.
“While disappointing, we feel comfortable with our NT estimates in part due to the revenue recognition dynamics with NVDA selling into EMS [electronic manufacturing services], and we ultimately believe these NT issues are transient in nature. We’d recommend investors continue to own NVDA.”
The firm said it’s sticking with top pick Tesla.
“Our OW rating and $410 price target are underpinned by our belief that Tesla’s capabilities in key areas of physical AI including data, robotics, energy storage, compute, manufacturing and space/comms/networking/infrastructure offer growth and margin opportunities that greatly exceed those of the traditional EV business which is under pressure.”
Key lowered its price target on the stock to $170 per share from $200 and said there’s too much uncertainty.
“We remain UW AAPL and lower our PT to $170 PT on a lower valuation multiple.”
KeyBanc said it sees a slew of negative catalysts ahead for AMD.
“AMD (mixed, fine-tuning estimates, downgrading to Sector Weight) – We are downgrading AMD from Overweight to Sector Weight given: 1) increasing concerns regarding the sustainability of its China AI business; 2) increasing risk to GM given a potential price war with INTC...”
Cantor said the crypto company is undervalued.
“We are initiating coverage of Coinbase with an OW rating and a 12-month $245 PT.”
TD Cowen said the fintech company is well positioned going forward.
“AFRM is one of the top performing BNPL brands in the U.S. with a full-suite POS lending capability vs peers, and likely the most pro consumer practices in the industry.”
Piper said the banking giant’s stock has an attractive valuation.
“While we have thought highly of WFC’s recent move from defense to offense, as well as the heightened pace of regulatory resolution, our only hang-up has been the stock’s valuation and (until recently) outperformance, which we felt appropriately captured the company’s improving fortunes.”
Goldman said it sees an attractive entry point for the biopharma company.
“We assume coverage on Eli Lilly & Co. (LLY) with a Buy rating (from Neutral) and a 12-month price target of $888 ($892 prior).”
Goldman said the company is a “defensive bellwether.”
“We assume coverage of JNJ with a Buy-rating (from Neutral) and a 12m PT of $172 ($157 prior) representing 15% upside.
Goldman said it sees too much macro uncertainty.
“As macroeconomic and geopolitical uncertainty increase, we are downgrading AAL shares to Sell as its relatively higher balance sheet leverage and operating leverage drive significantly larger cuts to our outlook vs. the industry.”
The firm said the jeans company has a compelling entry point.
“We are upgrading LEVI to Overweight with the macro-driven -50% pullback over the trailing 9 months providing an entry point at ~5x FY26 EBITDA to own a multi-year mid-teens(+) total return profile.”
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.